Abstract Background The use of Hepatitis C (HCV) NAT positive allografts remains unusual
and is clustered at few centers. We conducted a contemporary literature review to assess …

Summary HCV, HBV and HIV-positive liver transplantations can be accomplished safely and
are associated with equivalent outcomes when paired with appropriate recipients. The …

Several studies have explored the risk of graft dysfunction after liver transplantation (LT) in
recent years. Conversely, risk factors for graft discard before or at procurement have poorly …

Background. Transplanting hepatitis C viremic donor organs into hepatitis C virus (HCV)-
negative recipients is becoming increasingly common; however, practices for posttransplant …

Objective Lung transplants from donors with hepatitis C (HCV D+) have excellent outcomes,
but these organs continue to be declined. We evaluated whether (1) being listed to consider …

Introduction Transplants with hearts and lungs from donors with hepatitis C virus (HCV D+)
have been proven safe and effective since development of direct-acting antivirals, yet the …

Transplant candidates are facing incremental mortality risks on the waiting list. Here, we
report a novel strategy to expand the donor pool by including hepatitis C seropositive …

Background Despite excellent outcomes of heart transplants from hepatitis C virus (HCV)-
positive donors (D+), many candidates are not listed to even consider HCV D+ offers …

Liver transplantation (LT) remains the only curative option for patients suffering from end-
stage liver disease, acute liver failure and selected hepatocellular carcinomas and access to …

Background: Donor hepatitis-C (HCV) infection has historically represented a barrier to
kidney transplantation (KT). However, direct-acting antiviral (DAA) medications have …